New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
10:45 EDTGBIMGlobeImmune IPO indicated to open $11
News For GBIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
06:36 EDTGBIMGlobeImmune opens enrollment of randomized Phase 2 clinical trial for GI-6301
GlobeImmune announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination with radiation therapy in patients with chordoma is open for enrollment at the National Cancer Institute, or NCI. Christopher Heery, M.D., Head of the Clinical Trials Group at the NCI Laboratory of Tumor Immunology and Biology, is the principal investigator for the study. The Company believes that the GI-6301 Tarmogen, exclusively licensed to Celgen Corporation, has demonstrated promising initial results in chordoma patients evaluated in a recent Phase 1 study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use